The expanding clinical applications of GLP-1 medications are adding a new dimension to an already demanding task for employers and insurers: determining how to support access to emerging treatments while keeping benefits plans affordable. As utilization grows and clinical evidence develops, coverage decisions must account for both the potential value of these therapies and their longer-term financial implications.
For plan sponsors, the challenge is not simply deciding whether to cover GLP-1 medications, but working with insurers and other benefits partners to establish coverage arrangements that are clinically appropriate, financially sustainable and accessible to members.
Tina Cullen, AVP, Life & Health Claims at Co-operators, believes an equity-informed approach can help bring greater consideration to the different circumstances of plan members without adding unnecessary complexity to the process.
“Equity should be one of several important considerations when making coverage decisions,” says Cullen. “Clinical evidence, affordability, sustainability, and member experience all matter, but it’s equally important to understand whether different groups may be affected differently by how benefits are designed.”
An inclusion, diversity, equity and accessibility (IDEA) informed approach offers another useful perspective, helping inform coverage decisions and identify opportunities to support appropriate access to care.
Weight management illustrates some of the complications. Treatment needs vary according to medical history and existing health conditions, and members may also have different levels of access to the healthcare providers who assess their circumstances and recommend appropriate treatment.
“Members may experience access to healthcare differently depending on financial circumstances, geography, provider access, and existing health needs,” Cullen explains. She cautions against making assumptions about how particular populations experience healthcare. Clinical evidence, utilization trends and member experience can help plan sponsors assess whether their coverage approach continues to support appropriate access while balancing affordability and plan sustainability.
“Equity is not about treating everyone the same,” she says. “It’s about recognizing that people have different circumstances and considering those realities when designing benefits.”
As the clinical applications of GLP-1 therapies expand, their growing utilization is introducing new considerations for drug plan management and long-term affordability. New indications and products require ongoing assessment, while rising demand is adding pressure to employer-sponsored drug plans.
“GLP-1 medications have broadened the discussion beyond weight management to include metabolic health, chronic disease management, access to care, and plan sustainability,” Cullen says.
Higher utilization brings additional considerations for plan sponsors and insurers as they assess the long-term implications of coverage within the broader benefits program. Long-term treatment costs must be assessed against the available evidence, with spending on one category considered in relation to other healthcare needs.
Prior authorization and appropriate eligibility criteria can support clinically appropriate use while helping manage plan sustainability. As clinical evidence and utilization evolve, these approaches should be periodically reviewed to ensure they continue to support the intended coverage objectives.
Cullen recommends “evidence-based coverage, appropriate eligibility criteria, sound drug management, and regular review of outcomes and utilization.”
As clinical evidence continues to evolve, new indications, emerging evidence and changing utilization patterns can help inform whether an existing coverage approach continues to meet its intended objectives. Regular review can help ensure coverage remains aligned with clinical evidence, affordability and plan sustainability.
Cullen sees an IDEA-informed approach as a complement to established benefits governance, rather than a replacement for clinical or financial assessment.
Claims data provides valuable insight into treatment utilization and costs, although it may not capture the full range of members’ healthcare needs and experiences. Considering this information alongside broader clinical evidence and member perspectives can help plan sponsors and insurers make more informed coverage decisions.
For employers and insurers, the value lies in having a consistent basis for making decisions as new treatments enter the market. A framework that considers clinical effectiveness and financial sustainability, while remaining attentive to members' circumstances, can help organizations assess emerging therapies without treating each development as an entirely new coverage challenge.
Cullen believes the experience with GLP-1s offers a preview of how employers may need to assess other emerging therapies.
The GLP-1 discussion offers a useful example of how benefits decisions can adapt as clinical evidence develops and treatment options expand. Through ongoing collaboration, plan sponsors and insurers can assess emerging therapies in ways that recognize different member needs while preserving the affordability and long-term sustainability of coverage.
This article was produced in partnership with Co-operators